YDESW
YD Bio Limited
Price Chart
Latest Quote
$0.35
-0.01 (-2.78%)
Current Price
| Previous Close | $0.36 |
| Open | $0.36 |
| Day High | $0.37 |
| Day Low | $0.35 |
| Volume | 24,052 |
Stock Information
| Total Debt | $22K |
| Cash Equivalents | $3.13M |
| Revenue | $510K |
| Net Income | $-1.41M |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Sales | $510K |
| Income | $-1.41M |
| Book/sh | $4.57 |
Financial Ratios
| Quick Ratio | 12.91 |
| Current Ratio | 13.18 |
| Debt/Eq | 0.34 |
Returns & Margins
| ROA | -25.43% |
| ROE | -42.69% |
| Gross Margin | 30.44% |
| Operating Margin | -444.59% |
| Profit Margin | -276.58% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 0.08 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.69 |
| SMA50 | $0.70 |
| ATR | 0.0257 |
| Shares Float | 320K |
| Volatility | -0.18 |
| Rel Volume | 20.00 |
Performance History
| Week | -50.68% |
| Month | -50.68% |
| Quarter | -50.70% |
| YTD | -50.70% |
| 10 Years | -50.70% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $0.35 | 24,052 |
| 2026-06-04 | $0.71 | 0 |
| 2026-06-03 | $0.71 | 0 |
| 2026-06-02 | $0.71 | 0 |
| 2026-06-01 | $0.71 | 0 |
| 2026-05-29 | $0.71 | 0 |
| 2026-05-28 | $0.71 | 0 |
| 2026-05-27 | $0.71 | 0 |
| 2026-05-26 | $0.71 | 0 |
| 2026-05-22 | $0.71 | 0 |
| 2026-05-21 | $0.71 | 0 |
| 2026-05-20 | $0.71 | 0 |
| 2026-05-19 | $0.71 | 0 |
| 2026-05-18 | $0.71 | 0 |
| 2026-05-15 | $0.71 | 0 |
| 2026-05-14 | $0.71 | 0 |
| 2026-05-13 | $0.71 | 0 |
| 2026-05-12 | $0.71 | 0 |
| 2026-05-11 | $0.71 | 0 |
| 2026-05-08 | $0.71 | 0 |
| 2026-05-07 | $0.71 | 0 |
| 2026-05-06 | $0.71 | 0 |
About YD Bio Limited
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | |||
| Reconciled Cost Of Revenue | $236,093 | $260,468 | $196,686 |
| Cost Of Revenue | $429,407 | $355,004 | $196,686 |
| Total Revenue | $596,817 | $510,360 | $350,131 |
| Operating Revenue | $596,817 | $510,360 | $350,131 |
| Expenses | |||
| Interest Expense | $0 | $772 | $2,144 |
| Total Expenses | $5,865,135 | $1,972,783 | $357,247 |
| Other Income Expense | $-3,124,691 | $64,908 | $26,620 |
| Other Non Operating Income Expenses | $46,803 | $64,415 | $29,351 |
| Net Non Operating Interest Income Expense | $80,162 | $11,036 | $-1,854 |
| Interest Expense Non Operating | $0 | $772 | $2,144 |
| Operating Expense | $5,435,728 | $1,617,779 | $160,561 |
| Selling And Marketing Expense | $170,523 | $1,957 | $7,492 |
| General And Administrative Expense | $3,646,895 | $1,114,270 | $153,069 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-8,311,316 | $-1,411,559 | $13,560 |
| Net Interest Income | $80,162 | $11,036 | $-1,854 |
| Interest Income | $80,162 | $11,808 | $290 |
| Normalized Income | $-5,139,822 | $-1,411,953 | $15,658 |
| Net Income From Continuing And Discontinued Operation | $-8,311,316 | $-1,411,559 | $13,560 |
| Total Operating Income As Reported | $-5,271,721 | $-1,461,930 | $-9,847 |
| Net Income Common Stockholders | $-8,311,316 | $-1,411,559 | $13,560 |
| Net Income | $-8,311,316 | $-1,411,559 | $13,560 |
| Net Income Including Noncontrolling Interests | $-8,311,316 | $-1,411,559 | $13,560 |
| Net Income Continuous Operations | $-8,311,316 | $-1,411,559 | $13,560 |
| Pretax Income | $-8,312,847 | $-1,386,479 | $17,650 |
| Special Income Charges | $-3,403 | $493 | $-2,731 |
| Interest Income Non Operating | $80,162 | $11,808 | $290 |
| Operating Income | $-5,268,318 | $-1,462,423 | $-7,116 |
| Depreciation Amortization Depletion Income Statement | $16,246 | $10,199 | - |
| Depreciation And Amortization In Income Statement | $16,246 | $10,199 | - |
| Depreciation Income Statement | $16,246 | $10,199 | - |
| Gross Profit | $167,410 | $155,356 | $153,445 |
| Other | |||
| Tax Effect Of Unusual Items | $0 | $99 | $-633 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-4,931,793 | $-1,281,465 | $24,977 |
| Total Unusual Items | $-3,171,494 | $493 | $-2,731 |
| Total Unusual Items Excluding Goodwill | $-3,171,494 | $493 | $-2,731 |
| Reconciled Depreciation | $209,560 | $104,735 | $2,452 |
| EBITDA (Bullshit earnings) | $-8,103,287 | $-1,280,972 | $22,246 |
| EBIT | $-8,312,847 | $-1,385,707 | $19,794 |
| Diluted NI Availto Com Stockholders | $-8,311,316 | $-1,411,559 | $13,560 |
| Tax Provision | $-1,531 | $25,080 | $4,090 |
| Write Off | $3,403 | $-493 | $2,731 |
| Gain On Sale Of Security | $-3,168,091 | - | - |
| Research And Development | $1,602,064 | $491,353 | $0 |
| Selling General And Administration | $3,817,418 | $1,116,227 | $160,561 |
| Other Gand A | $3,646,895 | $1,114,270 | $153,069 |
Fetched: 2026-05-26
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Assets | |||
| Net Tangible Assets | $-5,465,402 | $3,910,211 | $22,994 |
| Total Assets | $13,779,397 | $6,864,226 | $321,212 |
| Total Non Current Assets | $4,109,207 | $3,396,344 | $49,488 |
| Non Current Prepaid Assets | $1,431,658 | $0 | - |
| Non Current Deferred Assets | $0 | $628,232 | $24,565 |
| Goodwill And Other Intangible Assets | $2,609,739 | $2,680,035 | $0 |
| Other Intangible Assets | $2,609,739 | $2,680,035 | - |
| Current Assets | $9,670,190 | $3,467,882 | $271,724 |
| Prepaid Assets | $1,070,770 | $35,453 | $16,788 |
| Inventory | $1,879,542 | $37,335 | $69,404 |
| Receivables | $712,263 | $262,796 | $98,434 |
| Taxes Receivable | $253,246 | $159,287 | $267 |
| Accounts Receivable | $167,477 | $86,582 | $98,167 |
| Allowance For Doubtful Accounts Receivable | $-6,598 | $-3,055 | $-3,769 |
| Gross Accounts Receivable | $174,075 | $89,637 | $101,936 |
| Cash Cash Equivalents And Short Term Investments | $6,007,615 | $3,132,298 | $87,098 |
| Cash And Cash Equivalents | $6,007,615 | $3,132,298 | $87,098 |
| Non Current Deferred Taxes Assets | - | $0 | $24,565 |
| Investmentin Financial Assets | - | $0 | $10,618 |
| Notes Receivable | - | $16,927 | $0 |
| Debt | |||
| Total Debt | $6,764 | $22,265 | $47,576 |
| Long Term Debt And Capital Lease Obligation | $0 | $5,684 | $0 |
| Current Debt And Capital Lease Obligation | $6,764 | $16,581 | $47,576 |
| Current Debt | - | $290 | $34,319 |
| Other Current Borrowings | - | - | $34,319 |
| Liabilities | |||
| Total Liabilities Net Minority Interest | $16,635,060 | $273,980 | $298,218 |
| Total Non Current Liabilities Net Minority Interest | $14,991,482 | $10,920 | $0 |
| Derivative Product Liabilities | $14,991,482 | $0 | - |
| Non Current Deferred Liabilities | $0 | $1,463 | - |
| Non Current Deferred Taxes Liabilities | $0 | $1,463 | - |
| Current Liabilities | $1,643,578 | $263,060 | $298,218 |
| Current Deferred Liabilities | $30,153 | - | $344 |
| Payables And Accrued Expenses | $1,606,661 | $246,479 | $250,298 |
| Payables | $1,203,216 | $64,119 | $237,196 |
| Other Payable | $4,261 | - | - |
| Accounts Payable | $413,290 | $26,866 | $17,976 |
| Other Non Current Liabilities | - | $3,773 | - |
| Current Notes Payable | - | $290 | $0 |
| Total Tax Payable | - | - | $1,969 |
| Equity | |||
| Common Stock Equity | $-2,855,663 | $6,590,246 | $22,994 |
| Total Equity Gross Minority Interest | $-2,855,663 | $6,590,246 | $22,994 |
| Stockholders Equity | $-2,855,663 | $6,590,246 | $22,994 |
| Gains Losses Not Affecting Retained Earnings | $213,936 | $45,072 | $47,211 |
| Retained Earnings | $-10,238,359 | $-1,927,043 | $-515,484 |
| Other | |||
| Ordinary Shares Number | $70,789,261 | $70,095,411 | $70,095,411 |
| Share Issued | $70,789,261 | $70,095,411 | $70,095,411 |
| Tangible Book Value | $-5,465,402 | $3,910,211 | $22,994 |
| Invested Capital | $-2,855,663 | $6,590,246 | $57,313 |
| Working Capital | $8,026,612 | $3,204,822 | $-26,494 |
| Capital Lease Obligations | $6,764 | $22,265 | $13,257 |
| Total Capitalization | $-2,855,663 | $6,590,246 | $22,994 |
| Additional Paid In Capital | $7,161,681 | $8,465,744 | $386,067 |
| Capital Stock | $7,079 | $6,473 | $105,200 |
| Common Stock | $7,079 | $6,473 | $105,200 |
| Long Term Capital Lease Obligation | $0 | $5,684 | $0 |
| Current Deferred Revenue | $30,153 | - | $0 |
| Current Capital Lease Obligation | $6,764 | $16,581 | $13,257 |
| Current Accrued Expenses | $403,445 | $182,360 | $13,102 |
| Dueto Related Parties Current | $785,665 | $37,253 | $217,251 |
| Net PPE | $67,810 | $88,077 | $14,305 |
| Accumulated Depreciation | $-28,576 | $-17,431 | $-7,949 |
| Gross PPE | $96,386 | $105,508 | $22,254 |
| Machinery Furniture Equipment | $87,916 | $81,810 | $9,139 |
| Buildings And Improvements | $8,470 | $23,698 | $13,115 |
| Properties | $0 | $0 | $0 |
| Finished Goods | $1,879,542 | $37,335 | $69,404 |
| Duefrom Related Parties Current | $291,540 | $16,927 | $0 |
| Investments And Advances | - | $0 | $10,618 |
| Available For Sale Securities | - | - | $10,618 |
Fetched: 2026-05-26
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-8,036,725 | $-4,133,675 | $-55,947 |
| Operating Activities | |||
| Operating Cash Flow | $-6,596,706 | $-1,222,681 | $-55,657 |
| Cash Flow From Continuing Operating Activities | $-6,596,706 | $-1,222,681 | $-55,657 |
| Operating Gains Losses | $3,168,200 | - | $466 |
| Investing Activities | |||
| Capital Expenditure | $-1,440,019 | $-2,910,994 | $-290 |
| Investing Cash Flow | $-1,440,019 | $-2,900,670 | $-290 |
| Cash Flow From Continuing Investing Activities | $-1,440,019 | $-2,900,670 | $-290 |
| Financing Activities | |||
| Issuance Of Capital Stock | $13,200,000 | $7,860,181 | $52,952 |
| Financing Cash Flow | $10,869,150 | $7,113,509 | $113,887 |
| Cash Flow From Continuing Financing Activities | $10,869,150 | $7,113,509 | $113,887 |
| Net Other Financing Charges | $-3,046,495 | $-713,695 | $93,544 |
| Net Common Stock Issuance | $13,200,000 | $7,860,181 | $52,952 |
| Common Stock Issuance | $13,200,000 | $7,860,181 | $52,952 |
| Other | |||
| Repayment Of Debt | $0 | $-32,977 | $-32,609 |
| Interest Paid Supplemental Data | $0 | $772 | $2,144 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 |
| End Cash Position | $6,007,615 | $3,132,298 | $87,098 |
| Beginning Cash Position | $3,132,298 | $87,098 | $30,142 |
| Effect Of Exchange Rate Changes | $42,892 | $55,042 | $-984 |
| Changes In Cash | $2,832,425 | $2,990,158 | $57,940 |
| Proceeds From Stock Option Exercised | $715,645 | $0 | $0 |
| Net Issuance Payments Of Debt | $0 | $-32,977 | $-32,609 |
| Net Long Term Debt Issuance | $0 | $-32,977 | $-32,609 |
| Long Term Debt Payments | $0 | $-32,977 | $-32,609 |
| Net Investment Purchase And Sale | $0 | $10,324 | $0 |
| Sale Of Investment | $0 | $10,324 | $0 |
| Net Intangibles Purchase And Sale | $0 | $-2,836,080 | $0 |
| Purchase Of Intangibles | $0 | $-2,836,080 | $0 |
| Net PPE Purchase And Sale | $-1,440,019 | $-74,914 | $-290 |
| Purchase Of PPE | $-1,440,019 | $-74,914 | $-290 |
| Change In Working Capital | $-1,685,561 | $46,329 | $-126,696 |
| Change In Other Current Liabilities | $-20,744 | $-12,239 | $-47,082 |
| Change In Payables And Accrued Expense | $1,386,562 | $223,791 | $9,996 |
| Change In Accrued Expense | $1,000,138 | $213,595 | $4,605 |
| Change In Payable | $386,424 | $10,196 | $5,391 |
| Change In Account Payable | $386,424 | $10,196 | $5,391 |
| Change In Prepaid Assets | $-850,261 | $-182,721 | $4,818 |
| Change In Inventory | $-1,842,207 | $28,517 | $-30,570 |
| Change In Receivables | $-358,911 | $-11,019 | $-63,858 |
| Changes In Account Receivables | $-84,298 | $6,297 | $-63,858 |
| Other Non Cash Items | $20,471 | $11,731 | $47,740 |
| Asset Impairment Charge | $3,403 | $-493 | $2,731 |
| Deferred Tax | $-1,463 | $26,576 | $4,090 |
| Deferred Income Tax | $-1,463 | $26,576 | $4,090 |
| Depreciation Amortization Depletion | $209,560 | $104,735 | $2,452 |
| Depreciation And Amortization | $209,560 | $104,735 | $2,452 |
| Amortization Cash Flow | $193,314 | $94,536 | $0 |
| Amortization Of Intangibles | $193,314 | $94,536 | $0 |
| Depreciation | $16,246 | $10,199 | $2,452 |
| Gain Loss On Investment Securities | $3,168,091 | - | - |
| Gain Loss On Sale Of PPE | $109 | $0 | $466 |
| Net Income From Continuing Operations | $-8,311,316 | $-1,411,559 | $13,560 |
| Change In Other Working Capital | - | $-614,137 | - |
Fetched: 2026-05-26